Healthcare
Shorter Clot-Prevention Therapy After Stent Placement Proves Effective for AFib Patients
New research shows a one-month course of dual clot-preventing therapy followed by single medication treatment is as effective as year-long dual therapy for preventing stroke, heart attack and death in atrial fibrillation patients with stents, while significantly reducing bleeding complications.
Standard Medical Care Outperforms Minimally Invasive Procedure for High-Risk Atrial Fibrillation Patients
New research presented at the American Heart Association's Scientific Sessions 2025 found that standard medical care, including blood thinners when appropriate, proved more effective than a catheter-based procedure for preventing stroke and other complications in older atrial fibrillation patients at high risk of bleeding and stroke.
Oral Cholesterol Medication Shows Promise as Alternative to Injectable Treatments
A new daily oral medication called enlicitide demonstrated up to 60% reduction in LDL cholesterol in clinical trials, potentially offering a more convenient option for high-risk patients who struggle to reach cholesterol targets with current treatments.
CRISPR Gene-Editing Therapy Shows Promise in Lowering Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human trial of CTX310, a CRISPR-based gene-editing therapy, demonstrated significant reductions in LDL cholesterol and triglycerides with sustained effects, potentially offering a one-time alternative to daily medications for patients with difficult-to-treat lipid disorders.
PCSK9 Inhibitor Shows Significant Cardiovascular Risk Reduction in High-Risk Patients Without Prior Heart Events
The VESALIUS-CV trial demonstrates that evolocumab reduces major cardiovascular events by 25% in patients with atherosclerotic disease or diabetes who haven't had prior heart attacks or strokes, potentially expanding preventive treatment options for millions at risk.
Novel Triple-Receptor Medication Shows Promise for Severe Triglyceride Reduction and Liver Health
A new investigational medication called DR10624 demonstrated significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia, potentially offering a new treatment approach for a condition with limited current options.
Fifth Annual Sickle Cell Caregiver Summit Focuses on Mental Wellness and Advocacy
The upcoming virtual Sickle Cell Caregiver Summit brings global attention to the critical role of caregivers in managing sickle cell disease while addressing mental health challenges and building advocacy skills.
Milevista Partners with Operation Smile to Raise $6.7 Million for Cleft Care by 2027
Milevista's partnership with Operation Smile combines experiential marketing expertise with global medical nonprofit capabilities to fund life-changing surgeries and comprehensive care for children with cleft conditions.
Voyageur Pharmaceuticals Appoints Financial Veteran Virginia Alling to Board, Accelerating U.S. Market Strategy
Voyageur Pharmaceuticals Ltd. has appointed Virginia Alling to its board of directors, strengthening its financial expertise to drive U.S. market expansion and capital market access for its pharmaceutical-grade barium and iodine contrast media products.
Immune Cell Surface Sugar Shedding Identified as Key Factor in Psoriasis Progression
New research reveals immune cells shed surface sugars before entering inflamed skin in psoriasis patients, potentially opening new treatment pathways for the chronic autoimmune condition.
Oncotelic Therapeutics Venture Advances Novel Breast Cancer Treatment to Clinical Trials
Sapu Nano, an Oncotelic Therapeutics venture, has received Australian ethics approval to begin clinical trials for Sapu003, an injectable form of everolimus that could significantly improve breast cancer treatment outcomes by enabling full drug absorption through intravenous delivery.
Olympus Announces Major Restructuring Strategy to Transform Endoscopy Care Through AI and Robotics
Olympus Corporation unveiled a comprehensive corporate strategy focused on advancing AI-powered endoscopy and robotics while implementing significant workforce reductions and organizational changes to drive innovation in medical technology.
Knecht Orthodontics Expands Access to Advanced Dental Care in Mont Belvieu
Knecht Orthodontics in Mont Belvieu is enhancing local healthcare access by offering comprehensive orthodontic treatments including traditional braces and Invisalign, supported by advanced technology and flexible payment options.
Strawberry Fields REIT Reports Record Q3 2025 Performance with Strategic Healthcare Facility Acquisitions
Strawberry Fields REIT achieved strong third-quarter 2025 results including record rental income and strategic expansion through $68.55 million in healthcare facility acquisitions, demonstrating robust growth in the healthcare real estate sector.
Soligenix Reports Q3 2025 Results with Key Clinical Milestones for Rare Disease Treatments
Soligenix Inc. announced positive clinical progress for its rare disease pipeline including upcoming Phase 2a psoriasis results and maintained safety profile for HyBryte™ in CTCL treatment, supported by sufficient funding through 2026.
Calotren Releases Official Ingredient Fact Sheet, Reaffirming 25-Year Commitment to Stimulant-Free Collagen Supplement
Top of the World Distributors has published an official Ingredient & Safety Fact Sheet for Calotren, emphasizing the supplement's 25-year history as a stimulant-free collagen product to address growing consumer demand for transparency in the health and nutrition industry.
Medical Marijuana Uncertainty Persists Despite Patient Success Stories
Despite compelling patient testimonials about cannabis providing relief where traditional medications failed, medical professionals and lawmakers remain divided on medical marijuana's role in healthcare, creating ongoing uncertainty in the rapidly evolving cannabis industry.
Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
Soligenix is progressing its phase 2a clinical trial of SGX302 for psoriasis treatment, showing encouraging safety and biological activity data that positions the therapy to address a $67 billion global market opportunity.
Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Georgia Law Firm Strengthens Medical Malpractice Advocacy Amid Complex Litigation Landscape
The Moses Firm reinforces its commitment to handling serious medical negligence cases, highlighting the complexity of malpractice litigation and the need for specialized legal and medical expertise to secure justice for victims.
Strawberry Fields REIT CEO Outlines Decade-Long Growth Strategy Amid Aging Population Trends
Strawberry Fields REIT's disciplined financial approach and focus on healthcare property acquisitions position the company to capitalize on America's aging demographic trends while maintaining consistent growth and perfect rent collection.
Datavault AI Grants Scilex Exclusive License for Biotech Exchange Platform in $2.55 Billion Deal
Datavault AI has licensed its AI-driven technology to Scilex for a biotech exchange platform that could address a $2 trillion pharmaceutical market, representing a major advancement in tokenizing and monetizing healthcare assets.
HeartBeam Submits Breakthrough ECG Technology for FDA Clearance
HeartBeam Inc. has submitted its innovative 12-lead ECG synthesis software to the FDA for clearance, representing a significant advancement in cardiac arrhythmia detection and management.
Jupiter Neurosciences Expands Brain Health Reach with Nugevia Supplement Line
Jupiter Neurosciences leverages its pharmaceutical expertise to launch Nugevia MND, a cognitive health supplement that addresses growing global demand for brain health solutions amid aging populations and represents a strategic bridge between clinical research and consumer wellness.
Sigyn Therapeutics Advances CardioDialysis™ to Address Cardiovascular Disease in Dialysis Patients
Sigyn Therapeutics is developing CardioDialysis™, a medical device that leverages existing dialysis infrastructure to treat cardiovascular disease in end-stage renal disease patients, who face a 67% mortality rate from heart conditions and limited benefit from traditional drug therapies.
Lantern Pharma to Host Q3 2025 Results Webcast, Highlighting AI-Driven Oncology Pipeline
Lantern Pharma will review its third-quarter 2025 financial results and AI platform developments during a November webcast, showcasing how artificial intelligence is accelerating cancer drug discovery and development.
Cybin Inc. Announces Q2 2025 Financial Results and Business Update Conference Call
Cybin Inc. will host a conference call on November 13, 2025, to discuss its second-quarter financial results and provide updates on its late-stage neuropsychiatry pipeline, including breakthrough-designated psychedelic treatments for major depressive disorder and generalized anxiety disorder.
Study Reveals Neurocognitive Decline in CNS Cancer Patients, Highlighting Treatment Challenges
Recent research demonstrates significant neurocognitive decline in central nervous system cancer patients, emphasizing the critical need for therapies that address both tumor control and cognitive preservation.
Medical Professional Launches Anti-Aging Skincare System Based on 34 Years of Clinical Experience
Dr. Barbara Sharief introduces an 8-product medical-grade skincare collection developed from her clinical expertise and personal commitment to aging without fillers or injectables, offering a holistic approach to skin health.
Cedars-Sinai Park Launches Immersive Digital Platform to Transform Senior Care Discovery
Portland's historic Cedars-Sinai Park senior campus has unveiled a storytelling-driven digital experience that reimagines how families explore senior care options through emotional connection rather than clinical information.